bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate
CORTISPORIN (bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate) by Monarch Therapeutics is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics. First approved in 1957.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Cortisporin is a topical ointment combining two bactericidal antibiotics (bacitracin zinc, neomycin sulfate, polymyxin B sulfate) with hydrocortisone to treat superficial bacterial infections of the external auditory canal. The antibiotics disrupt bacterial cell membranes and inhibit protein synthesis, while hydrocortisone reduces inflammation and edema.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating contraction phase requiring transition planning and cost-focused portfolio management rather than growth investment.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on CORTISPORIN at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Cortisporin positions professionals in a mature, declining market phase with limited growth opportunities and heavy emphasis on cost management and defensive strategies. Roles tend to focus on maintaining market share, managing generic transition, and optimizing operational efficiency rather than innovation or expansion.